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Abstract 
Background: Candida susceptibility commonly occurs in breast cancer patients. Of which, Candida albicans is 
considered as a common pathogen causing candidiasis. Martinella iquitosensis (Bignoniaceae) is one of the species 
belonged to Martinella, distributed widely in Amazon basin. Its root extract yielded two complex substituted tetrahy‑
droquinolines, Martinelline and Martinellic acid which were the first natural non‑peptide bradykinin receptor antago‑
nists identified.
Findings: In this study, a novel martinelline type analogue, named 2,3,3a,4,5,9b‑hexahydro‑8‑phenoxy‑4‑(pyridin‑2‑yl)
furo[3,2‑c]quinoline, was synthesized and its preliminary anticancer activity and antifungal potential were investigated. 
This compound showed potential anticancer activity against MDAMB‑231 breast cancer cells. Meanwhile it could 
enhance the fungistatic activity of miconazole against Candida albicans.
Conclusions: These findings provide an implication for the continue investigation and development of martinelline 
type analogues as therapeutic agents in the future.
Keywords: Biological activity, Candida albicans, Hexahydrofuro[3,2‑c]quinoline, Martinelline type analogue
© 2016 Chung et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Breast cancer patients are commonly susceptible to can-
didiasis. Candida albicans (C. albicans) is one of the 
opportunistic fungi especially observed in immunocom-
promised patients (Calderone and Fonzi 2001), such as 
cancer patients. Previous studies have investigated the 
prevalence of candidiasis in cancer patients. Among 845 
women with multiple lymph node positive or metastatic 
breast carcinoma receiving high-dose chemotherapy and 
autologous bone marrow transplantation at Duke Uni-
versity Medical Center during 1992–1997, 29 of them 
(3.4  %) developed candidemia. Of which, 23  % of them 
were found to be infected with C. albicans. The mortal-
ity was highest for the women who were infected by C. 
albicans (71  %) (Gottfredsson et  al. 2003). In 2005, 400 
adult patients with the hematological malignancy, head 
neck or solid tumor (including breast cancer) were 
recruited randomly into the study on admission to the 
regional cancer center of the Norfolk and Norwich Uni-
versity Hospital. There were 56.8  % (227 of 400) of all 
cancer patients and 18.9 % (43 of 227) of those who had 
clinical and microbiological evidence of oral candidiasis. 
Among 269 yeast isolates recovered from 227 patients, 
C. albicans was the most common yeast (74 %) causing 
colonization and infection (Schelenz et al. 2011).
Martinella can be used as indigenous medicine for 
eye disease caused by bacteria in various ethnolinguis-
tic groups of some South American countries (Witherup 
et  al. 1995). Martinella iquitosensis (Bignoniaceae), one 
of the species belonged to Martinella, is a tropical plant 
with dark purple corolla in South American and distrib-
uted widely in Amazon basin (Zuntini and Lohmann 
2014). Its root extract yielded two complex substituted 
tetrahydroquinolines, Martinelline and Martinellic 
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acid (Fig.  1a) which were the first natural non-peptide 
bradykinin receptor antagonists identified by Witherup 
et  al. (1995). Afterwards, the studies on the synthesis 
of new compounds with this interesting core have been 
increased. For instance, hexahydro-2H-pyrano[3,2-c]
quinolines were found to be a potent agent against patho-
genic gram-negative bacteria and Magesh et  al. discov-
ered that one of the synthesized compounds exhibits 
good bacteriolytic activity against Virbio vulnificus and 
Vibrio parahaemolticus (Magesh et  al. 2004). Another 
research group (Kantevari et  al. 2011) also synthesized 
a series of hexahydro-2H-pyrano[3,2-c]quinolines and 
studied their activity against the Mycobacrtium tuber-
culosis H37Rv. Three of the synthesized compounds 
showed a comparable activity as ethambutol. In addition, 
it was reported that hexahydro-2H-pyrano[3,2-c]quino-
lines could be used as selective σ1 receptor ligand for the 
treatment of pain (Diaz et al. 2013).
Heterocyclic compounds are important candidates in 
the development of new class of structural entities for 
medicinal applications. Quinoline is a heterocyclic aro-
matic nitrogen containing compound characterized by 
a double-ring structure that has a benzene ring fused to 
pyridine at two adjacent carbon atoms (Keri and Patil 
2014). Among these structures, tetrahydroquinoline 
derivatives demonstrated extensive biological activi-
ties. They included anticancer (Subramanian et al. 2011), 
antioxidant (Dorey et  al. 2000) and antifungal (Vargas 
Méndez et  al. 2010) activity. The construction and ste-
reochemistry of the tricyclic ring system have also been 
recently reported (Calleja et  al. 2014). In the previous 
years, we have prepared and studied some simple 2-sub-
situted terahydroquinoline alkaloid analogues as anti-
tumor agents possessing notable cytotoxicity towards 
human Hep3B heptocellular carcinoma cells (Lam et al. 
2013). In addition, we have reported the antimicrobial 
activity of some novel synthesized quinoline analogues 
(Lam et al. 2014; Chung et al. 2015). Inspired by unique 
core moiety of Martinelline and the reported promis-
ing bioactivity of tetrahydroquinolines and their related 
natural product analogues, we have designed compound 
1 (Fig. 1b) and its potential biological activity was tested 
on MDAMB-231 breast cancer cells and C. albicans.
Strategically, we aimed to develop a simple and mild 
reaction pathway for the synthesis of compound 1 using 
one-pot multicomponent reaction with substituted ani-
line, aldehyde and alkene. Various catalysts, such as 
NbCl5 (da Silva et al. 2014), Fe2(SO4)·xH2O (Khan et al. 
2011; Das et  al. 2014), In(OTf)3 (Priestley et  al. 2013) 
and BiCl3 (Kouznetsov et  al. 2011) were reported to be 
effective for this reaction. Particularly, bismuth and 
its compounds are recognized as safe and green Lewis 
acid catalysts (Leonard et  al. 2002; Mohan 2010). With 
increasing concern on the advancement of “green reac-
tion” in last decade, the application of bismuth(III) com-
pounds and their important roles in organic synthesis 
have been clearly addressed in recent researches (Gas-
pard-Iloughmane and Le Roux 2004; Bothwell et al. 2011; 
Ollevier 2013). Herein, we report a bismuth(III)-cata-
lyzed synthesis of substituted tetrahydroquionlines.
Methods
General procedure for the synthesis 
of 2,3,3a,4,5,9b‑hexahydro‑8‑phenoxy‑4‑(pyridin‑2‑yl)
furo[3,2‑c]quinoline (compound 1)
All reagents were purchased from Sigma-Aldrich. All the 
synthesized compounds were characterized by 1H NMR, 
13C NMR, mass spectrometry and X-ray crystallography. 
Fig. 1 Structure of a Martinellic acid and Martinelline; b compound 1; c MOLECULAR structure of compound 1
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NMR spectra were recorded on a Bruker DPX400 Fou-
rier transform spectrometer using CDCl3 as solvent 
unless otherwise specified. X-ray crystallographic analy-
sis was performed by Bruker D8_VENTURE PHOTON 
100. To a mixture of 2-Pyridinecarboxaldehyde (1.0 mol 
equiv) and 4-Phenoxyaniline (1.2  mol equiv) was added 
in solvent (2  mL) and stirred. Catalyst (0.2  mol equiv) 
and 2,3-Dihydrofuran (1.2  mol equiv) were then added. 
The reaction mixture was stirred at room temperature 
for 1.5 h. Solvent was then removed and the residue was 
extracted with dichloromethane. The organic layer was 
washed with 10 % Na2CO3 solution and water. Dried over 
anhydrous Na2SO4 and removed the solvent by rotary 
evaporator. The crude product was purified by silica gel 
column chromatography.
Synthesis and characterization of compound 1
1H NMR (400 MHz, CDCl3): δ 1.55–1.57 (m, 1H), 2.03–
2.09 (m, 1H), 3.07–3.14 (m, 1H), 3.76–3.80 (m, 2H), 4.53 
(s, 1H), 4.83 (d, 1H, J = 2.8 Hz), 5.30 (d, 1H, J = 8.0 Hz), 
6.70 (d, 1H, J = 8.8 Hz), 6.84–6.98 (m, 1H), 7.00–7.06 (m, 
3H), 7.11 (d, 1H, J = 2.4 Hz), 7.25–7.27 (m, 1H), 7.31–7.33 
(m, 2H), 7.50 (d, 1H, J = 8.0 Hz), 7.75–7.77 (m, 1H), 8.64 
(d, 1H, J = 4.4 Hz); 13C NMR (100 MHz, CDCl3): δ 24.40, 
43.33, 57.67, 66.62, 75.91, 116.17, 117.60, 120.43, 120.56, 
120.98, 122.18, 122.42, 123.85, 129.53, 136.79, 140.93, 
149.10, 149.16, 158.66, 160.13; HRMS (ESI): Calcd. for 
C22H21N2O2 [M + H]+, 345.1598. found 345.1597. Melt-
ing point = 132.4–134.2 °C. Optimized yield = 26.8 %.
[3‑(4,5‑dimethylthiazol‑2‑yl)‑5‑(3‑carboxymethoxyphenyl) 
‑2‑(4‑sulfophenyl)‑2H‑tetrazolium] (MTS) assay  
and cellular morphology
MDAMB-231 cells were obtained from American Type 
of Culture Collection. Changes in the cellular viability of 
compound 1-treated cells were monitored using the MTS 
activity assay (20). Briefly, MDAMB-231 breast carcinoma 
cells were seeded at day 0. After 24 h, complete medium 
was changed and compound 1 was added at different con-
centrations (starting with 50 µM containing 0.1 % dime-
thyl sulfoxide (DMSO) as vehicle). Doxorubicin at 8 µM 
was used as a positive control. After 48 h of incubation, 
incubation medium was removed and fresh medium with 
MTS (Promega)/phenazine methosulfate as electron 
coupling agent mixed solution was added. Lastly, optical 
absorbance was determined at 490  nm using a micro-
plate reader (Perkin Elmer Victor V) according to the user 
manual. Additionally, any morphological changes asso-
ciated with compound 1 and doxorubicin treated breast 
cancer cells were recorded under an inverted microscope 
after fixing the cells with trichloroacetic acid and cellu-
lar protein was stained with sulforhodamine B after 24 h 
(Kok et al. 2007; Lam et al. 2015a, b).
Determination of minimum inhibitory concentration (MIC) 
and sensitization assay
Candida albicans was obtained from American Type of 
Culture Collection. The MIC values of synthesized com-
pound 1 and miconazole nitrate were determined by the 
broth dilution method. Various concentrations of com-
pound 1 and miconazole were loaded from a starting 
concentration of 50  µM containing 0.1  % dimethyl sul-
foxide (DMSO) as vehicle and they were diluted serially. 
DMSO (0.1 %) was used as a vehicle control. The fungal 
samples were then incubated at 37 °C for 48 h. The mini-
mum concentrations of compound 1 and miconazole that 
induced a complete growth inhibition would be deter-
mined as their MIC values. For sensitization study, with 
compound 1 at 50 µM, miconazole was added at a start-
ing concentration of 1.56, 0.78 and 0.39 µM respectively. 
After incubation, the fungal samples were treated with 
MTS/PMS as above (Lam et al. 2015a).
Results and discussion
Synthesis of compound 1
We first screened different metal salts as catalyst for this 
reaction (Table 1). It was found that only metal(III) salts 
(Table 1, Entry 5–7) gave our desired compound 1 and, 
in particular, bismuth(III) nitrate pentahydrate provided 
the highest yield among all the selected catalysts. With 
such preliminary screening, we used Bi(NO3)3·5H2O as 
catalyst for further optimization of the reaction under 
various conditions aiming to enhance the product yield 
(Table 2). It is noted that addition of catalyst in 0.2 mol 
equivalent and the reaction carried in ethanol (Table  2, 
Entry 7) provided the best yield. With the present work, 
further investigation is ongoing to develop a greener and 
more effective reaction for the synthesis of compound 1.
Anticancer activity of compound 1
Compound 1 at 50 µM (~17 µg/ml) could readily induce 
cell death on MDAMB-231 cells with significant cel-
lular morphological changes when compared with the 
untreated control (Fig.  2a) such as cell rounding and 
shrinkage (Fig. 2b) which were similar to those from the 
positive reference, doxorubicin (Fig.  2c) at 8  µM after 
24 h. As shown in Fig. 2d, a dose dependent cytotoxicity 
of compound 1 on MDAMB-231 breast cancer cells was 
observed after a 48 h of incubation.
MIC of compound 1
The MIC value of miconazole on C. albicans was found 
to be 3 µM. Compound 1, however, did not exhibit anti-
fungal activity on C. albicans of up to 50 µM. However, 
we found that compound 1 could enhance the antifun-
gal activity of miconazole on C. albicans. In the sub-
sequent tests, compound 1 was added simultaneously 
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with different concentrations of miconazole. As shown 
in Fig.  3, compound 1 could significantly potentiate the 
antifungal action of miconazole. Recently, we have shown 
that corilagin could sensitize Hep3B hepatoma cells to 
cisplatin and doxorubicin (Gambari et al. 2014). Here we 
suggest that compound 1 at 50  µM could significantly 
improve the fungistatic property of miconazole against C. 
albicans.
Table 1 Catalyst screening to optimize the product yield
All the reactions were carried out at room temperature in acetonitrile (ACN) for 1.5 h
N.D. not detected








Table 2 Optimization on the product yield using Bi(NO3)3·5H2O 
All the reactions were carried out at room temperature and catalyst (0.2 mol equiv) was added
a Catalyst (0.05 mol equiv) was added
b Catalyst (0.1 mol equiv) was added
c 0.1 M nitric acid was used and no metal catalyst was added
d The reaction was carried out under reflux
Entry Solvent Reaction time (h) Yield (%)
1a ACN 1.5 6.8
2b ACN 1.5 10.2
3 ACN 1.5 19.6
4 CH2Cl2 1.5 17.1
5 Water 1.5 9.1
6c Water 1.5 12.0
7 Ethanol 1.5 22.2
8d ACN 1.5 21.8
9 Ethanol 0.5 26.8
10 Ethanol 3 25.3
11 Ethanol 7 18.6
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Conclusions
In this work, the synthesis and preliminary in  vitro bio-
logical application of a novel martinelline type analogue, 
named 2,3,3a,4,5,9b-hexahydro-8-phenoxy-4-(pyridin-
2-yl)furo[3,2-c]quinoline, were described. Interestingly, this 
compound showed potential anticancer activity against 
MDAMB-231 breast cancer cells and it could simultane-
ously potentiate the fungistatic activity of miconazole 
against a common human pathogenic fungus, C. albicans. 
As the obtained compound 1 consists of three chiral cen-
tres, there should be eight stereoisomers exist. Further 
work will be carried out to isolate each isomer and inves-
tigate their individual potential biological activity in order 
to elucidate if chirality is important in this group of com-
pounds from the pharmaceutical point of view.
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Fig. 2 a–c Cellular morphology of MDAMB‑231 cells after 24 h: a Untreated control; b compound 1 at 50 µM; c Doxorubicin at 8 µM as positive ref‑
erence; and d MTS activity assay to determine the effect of compound 1 on MDAMB‑231 cells after 48 h. Reported results represent the mean ± SD 
from triplicate tests. This figure shows a representative experiment taken from three independent experiments giving similar results
Fig. 3 MTS activity assay to determine the effect of miconazole alone 
and micronazole with compound 1 (50 µM) on C. albicans. Reported 
results represent the mean ± SD from triplicate tests. This figure 
shows a representative experiment taken from three independent 
experiments giving similar results
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